Verastem, Inc. (VSTM)
7.335
0.00 (0.00%)
USD |
NASDAQ |
Sep 16, 16:00
7.44
+0.10
(+1.43%)
After-Hours: 20:00
Verastem Enterprise Value : 612.11M for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 612.11M |
| September 14, 2026 | 627.49M |
| September 11, 2026 | 610.30M |
| September 10, 2026 | 637.45M |
| September 09, 2026 | 666.40M |
| September 08, 2026 | 679.07M |
| September 04, 2026 | 689.93M |
| September 03, 2026 | 670.02M |
| September 02, 2026 | 673.64M |
| September 01, 2026 | 636.54M |
| August 31, 2026 | 601.25M |
| August 28, 2026 | 601.25M |
| August 27, 2026 | 615.73M |
| August 26, 2026 | 616.64M |
| August 25, 2026 | 588.59M |
| August 24, 2026 | 568.68M |
| August 21, 2026 | 571.40M |
| August 20, 2026 | 565.06M |
| August 19, 2026 | 608.04M |
| August 18, 2026 | 620.26M |
| August 17, 2026 | 597.63M |
| August 14, 2026 | 543.35M |
| August 13, 2026 | 551.49M |
| August 12, 2026 | 576.82M |
| August 11, 2026 | 585.87M |
| Date | Value |
|---|---|
| August 10, 2026 | 562.35M |
| August 07, 2026 | 557.82M |
| August 06, 2026 | 482.72M |
| August 05, 2026 | 479.10M |
| August 04, 2026 | 473.68M |
| August 03, 2026 | 462.82M |
| July 31, 2026 | 472.77M |
| July 30, 2026 | 499.91M |
| July 29, 2026 | 491.77M |
| July 28, 2026 | 511.68M |
| July 27, 2026 | 498.11M |
| July 24, 2026 | 495.39M |
| July 23, 2026 | 507.15M |
| July 22, 2026 | 480.91M |
| July 21, 2026 | 490.87M |
| July 20, 2026 | 468.25M |
| July 17, 2026 | 493.58M |
| July 16, 2026 | 470.06M |
| July 15, 2026 | 466.44M |
| July 14, 2026 | 451.96M |
| July 13, 2026 | 433.86M |
| July 10, 2026 | 448.34M |
| July 09, 2026 | 436.58M |
| July 08, 2026 | 407.62M |
| July 07, 2026 | 386.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.724B |
| Dianthus Therapeutics, Inc. | 4.856B |
| Alnylam Pharmaceuticals, Inc. | 31.54B |
| Anika Therapeutics, Inc. | 266.68M |
| Savara, Inc. | 937.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.67M |
| Revenue (Quarterly) | 40.08M |
| Total Expenses (Quarterly) | 74.75M |
| EPS Diluted (Quarterly) | -0.3463 |
| Gross Profit Margin (Quarterly) | 89.92% |
| Profit Margin (Quarterly) | -86.51% |
| Earnings Yield | -33.54% |
| Normalized Earnings Yield | -27.34 |